Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-08-20
2002-09-10
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S262100
Reexamination Certificate
active
06448227
ABSTRACT:
This is a 371 of PCT/EP00/01419 filed Feb. 22, 2000. From European patent 0 327 612 B1, the use is known of S-acetyl glutathione as a medical substance with various different indications. S-acetyl glutathione is the mono-acetyl-(thio)-ester of glutathione (gamma-glutamyl-cysteinyl-glycine) with the following structure formula:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to a mixture containing S-acetyl glutathione and Aciclovir (ACV) as medication against the Herpes Simplex virus or the Varicella Zoster virus.
2. Description of the Prior Art
A process for the manufacture of S-acetyl glutathione is disclosed in U.S. Pat No. 2,760,956.
Aciclovir (ACV) is a known medication for use against the Herpes Simplex virus (HSV). Aciclovir is an abbreviated nomenclature (INN) for 9-[(2-hydroxyethoxy)methyl)guanine.
SUMMARY THE INVENTION
It has now been recognized that, surprisingly, the combination of S-acetyl glutathione and ACV has a strong synergetic effect against the Herpes Simplex virus (HSV), especially against HSV-1, as well as against the Varicella Zoster virus (VZV).
REFERENCES:
patent: 761 09 3 (1956-11-01), None
patent: 92 03 146 (1992-03-01), None
O'Brien W J et al: “Effects of nucleoside antivirals and their metabolites on the corneal endothelium.” Current Eye Research, (1981) 1 (4) 243-8.
Kurokawa M et al: “Efficacy of Traditional Herbal Medicines in Combination with Acyclovir Against Herpes Simplex Virus Type 1 Infection In Vitro and In Vivo” Antiviral Research, NL, Elsevier Science BV., Amsterdam, Bd. 27, Nr. 1/02, 1995, pp. 19-37.
Pancheva S. et al: “Effect of combined acyclovir and ribavirin on experimental Herpes simplex virus type 1 keratoconjunctivitis in rabbits” Acta Microbiologica Bulgarica, Bd. 29, 1993, pp. 61-64, XP000911006.
Mucsi I et al: “Combined Effects of Flavonoids and Acyclovir Against Herpesviruses in Cell Cultures” Acta Microbiologica Hungarica, Hu, Akad. Kiado, Budapest, Bd. 39, Nr. 2, 1992, pp. 137-147.
Holliday J et al: “Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine.” Antiviral Research, (Sep. 1991) 16 (2) 197-203.
Field H J et al: “Effect of Acycloguanosine Treatment on Acute and Latent Herpes Simplex Infections in Mice” Antimicrobial Agents and Chemotherapy, US, American Society for Microbiology, Washington, DC, Bd. 15, Nr. 4, Apr. 1, 1979 pp. 554-561, XP000568622.
Field Milton M.
Henley III Raymond
LandOfFree
Therapeutically effective substance mixture does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutically effective substance mixture, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutically effective substance mixture will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2872603